Zum Hauptinhalt springen

Darminfektion mit Clostridioides difficile

Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:
Definition:
Darminfektion verursacht durch das Bakterium Clostridioides difficile, meist nach Antibiotikabehandlung.
Häufigkeit:
Zunehmend durch häufige Anwendung von Breitbandantibiotika; einer der häufigsten Erreger von Nosokomialinfektionen.
Symptome:
Durchfall, selten blutig, Bauchschmerzen, Fieber.
Befunde:
Klinisch geschwächter Allgemeinzustand, evtl. Dehydrierung, bei schweren Verläufen pseudomembranöse Kolitis.
Diagnostik:
Toxinnachweis im Stuhl, Endoskopie.
Therapie:
Leichte Formen symptomatisch, sonst Antibiotikagabe, bei schweren Verläufen gelegentlich operative Maßnahmen.
  • Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten. Gastrointestinale Infektionen und Morbus Whipple. AWMF-Leitlinie-Nr. 021-024. S2k, Stand 2015. www.awmf.org 
  • Robert Koch-Institut. Infektionskrankheiten. Clostridioides difficile. RKI-Ratgeber für Ärzt*innen. Stand 02.02.2018. www.rki.de 
  1. Schroeder MS. Clostridium difficile - associated diarrhea. Am Fam Physician 2005; 71: 921-8. PubMed  
  2. Starr J. Clostridium difficile associated diarrhoea: diagnosis and treatment. BMJ 2005; 331: 498-501. www.ncbi.nlm.nih.gov  
  3. Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten. Gastrointestinale Infektionen und Morbus Whipple. AWMF-Leitlinie-Nr. 021-024, Stand 2015. www.awmf.org www.awmf.org  
  4. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012; 107: 89-95. PubMed  
  5. Robert Koch Institut. Infektionskrankheiten, Clostridioides difficile, RKI-Ratgeber, Berlin, Stand: 02.02.2018. www.rki.de  
  6. Edith Bennack, Antibiotikainduzierte Diarrhö-Von lästig bis lebensbedrohlich, Pharmazeutische Zeitung, 09.05.2016. www.pharmazeutische-zeitung.de  
  7. Lübbert C, John E, von Müller L: Clostridium difficile infection— guideline-based diagnosis and treatment. Dtsch Arztebl Int 2014; 111: 723–31. www.aerzteblatt.de  
  8. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498. PubMed  
  9. Winslow BT, Onysko M, Thaompson KA, et al. Common questions about Clostridium difficile infection. Am Fam Physician. 2014 Mar 15;89(6):437-442. PubMed  
  10. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg 2002; 235: 363-72. PubMed  
  11. Petrella LA, Sambol SP, Cheknis A, et al. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic c. difficile BI strain. Clin Infect Dis 2012; 55: 351-7. PubMed  
  12. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67: 742-8. PubMed  
  13. Ziegler A. Behandlung der Antibiotika-assoziierten Diarrhö. Deutsche Apotheker Zeitung 2008, Nr. 40, S. 58, 02.10.2008. www.deutsche-apotheker-zeitung.de  
  14. Brown KA, Khanafer N, Daneman N, Fisman DN. Antibiotics and the risk of community-associated Clostridium difficile infection (CDI): a meta-analysis. Antimicrob Agents Chemother 2013. doi:10.1128/AAC.02176-12 DOI  
  15. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013. pmid: 23620467 PubMed  
  16. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of clostridium difficile infection. Clin Infect Dis 2011; 53: 42-8. PubMed  
  17. Fischer A et al. Infektionen mit Clostridium difficile – neue Therapiemöglichkeiten, CMExtra, 02.05.2015. cme.mgo-fachverlage.de  
  18. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: Meta-analysis. Am J Gastroenterol 2012; doi: 10.1038/ajg.2012.108. DOI  
  19. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010; 170: 772-8. PubMed  
  20. Howell MD, Novack V, Grgurich P. Iatrogenic gastric acid suppression and the risk of nosocomial clostridium difficile infection. Arch Intern Med 2010; 170: 784-90. PubMed  
  21. Miller M, Gravel D, Mulvey M, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201. www.ncbi.nlm.nih.gov  
  22. Zacharioudakis IM, Zervou FN, Pliakos EE, et al. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: A systematic review and meta-analysis. Am J Gastroenterol 2015 Mar; 110:381. PMID: 25732416 PubMed  
  23. Im GY, Modayil RJ, Lin CT, et al. The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol 2011; 9: 1072-7. PubMed  
  24. Chia J-H, Wu T-S, Wu T-S, et al. Clostridium innocuum is a vancomycin-resistant pathogen that may cause antibiotic-associated diarrhea. Clin Microbiol Infect 2018 Feb 17; pii: S1198-743X(18)30188-5: Epub ahead of print. pmid:29458157 PubMed  
  25. Wanahita A, Goldsmith EA, Marino BJ, Musher DM. Clostridium difficile infection in patients with unexplained leukocytosis. Am J Med. 2003;115(7):543–546. www.ncbi.nlm.nih.gov  
  26. Lieberknecht, S., Vehreschild, M.J.G.T. Update Clostridioides-difficile-Infektion. Gastroenterologe 15, 168–177 (2020). doi.org  
  27. O`Horo JC, Jones A, Sternke M, et al. Molecular Techniques for Diagnosis of Clostridium difficile Infection: Systematic Review and Meta-analysis. . Mayo Clin Proc 2012; 87: 643-51. PubMed  
  28. Ash L, Baker ME, O'Malley CM Jr et al.: Colonic abnormalities on CT in adult hospitalized patients with Clostridium difficile colitis: prevalence and significance of findings. American Journal of Radiology 2006; 186: 1393–400. www.ncbi.nlm.nih.gov  
  29. Wenisch JM, Schmid D, Kuo HW, et al. Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2012; 56: 1974-8. PubMed  
  30. Der Arzneimittelbrief. Erkrankungen durch Clostridium difficile - Epidemiologie, Therapie, Kosten. Jahrgang 51, Nr. 9, Berlin, September 2017 www.der-arzneimittelbrief.de  
  31. Drekonja D, Reich J, Gezahegn S, et al. Fecal microbiotica transplantation for Clostridium difficile infection: A systematic review. Ann Intern Med 2015; 162: 630-8. doi:10.7326/M14-2693 DOI  
  32. Kleger A, Schnell J, Essig A, Case report: Fecal transplant in refractory clostridium difficile colitis. Dtsch Arztebl Int 2013; 110(7): 108–15. www.aerzteblatt.de  
  33. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol. 2014 ;48:693-702. doi: 10.1097/MCG.0000000000000046. journals.lww.com  
  34. Kelly CR, Yen EF, Grinspan AM, et al. Fecal Microbiota Transplant is Highly Effective in Real-World Practice: Initial Results from the FMT National Registry. Gastroenerology 2020. doi:10.1053/j.gastro.2020.09.038. www.gastrojournal.org  
  35. Lee CH, Steiner T, Petrof EO, et al. Frozen vs Fresh Fecal Microbiota Transplantation and clinical resolution of diarrhea in patients with recurrent clostridium difficile infection: A randomized clinical trial. JAMA 315; 142-9: 10.1001/jama.2015.18098. doi:10.1001/jama.2015.18098 DOI  
  36. Kao D, Roach B, Solva M, et al. Effect of Oral Capsule– vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection A Randomized Clinical Trial. JAMA 2017 Nov 28; 318(20): 1985-1993. pmid:29183074 PubMed  
  37. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent clostridium difficile. N Engl J Med 2013; 368:407-15. PubMed  
  38. Butler M, Olson A, Drekonja D, et al. Early Diagnosis, Prevention, and Treatment of Clostridium difficile: Update Internet. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Mar. (Comparative Effectiveness Reviews, No. 172.) Available from: http://www.ncbi.nlm.nih.gov/books/NBK361173/ www.ncbi.nlm.nih.gov  
  39. Andreas Stallmach et all.. Fäkaler Mikrobiota-Transfer. Deutsches Ärzteblatt 2020; 117: 31-8. doi:10.3238/arztebl.2020.0031 DOI  
  40. Lowy I, Molrine DC, Leav BA, et al. Treatment with monclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205. New England Journal of Medicine  
  41. Pharmazeutische Zeitung online Nachrichten 1.2017 www.pharmazeutische-zeitung.de  
  42. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24: 699-706. PubMed  
  43. Oughton MT, Loo VG, Dendukuri N, et al. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol 2009; 30: 939-44. PubMed  
  44. Stone SP, Fuller C, Savage J, et al. Evaluation of the national Cleanyourhands campaign to reduce Staphylococcus aureus bacteraemia and Clostridium difficile infection in hospitals in England and Wales by improved hand hygiene: four year, prospective, ecological, interrupted time series study. BMJ 2012; 344: e3005. BMJ (DOI)  
  45. Hüttemann D. Die unbeachtete Pandemie Impfen gegen resistente Bakterien, Pharmazeutische Zeitung, 03.03.2020. www.pharmazeutische-zeitung.de  
  46. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010; 105: 1636. PubMed  
  47. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013. doi: 10.1016/S0140-6736(13)61218-0 DOI  
  48. Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database of Systematic Reviews 2011; 11: CD004827. pubmed.ncbi.nlm.nih.gov  
  49. Goldenberg JZ, Ma SSY, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, Guyatt GH, Johnston BC. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD006095. pubmed.ncbi.nlm.nih.gov  
  50. Bennack E. Antibiotikainduzierte Diarrhö Von lästig bis lebensbedrohlich. Pharmazeutische Zeitung online 19/2016. Zugriff 07.01.2018 www.pharmazeutische-zeitung.de  
  51. Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004; 171: 466-72. pubmed.ncbi.nlm.nih.gov  
  • Kristine Scheibel, Dr. med., Fachärztin für Allgemeinmedizin, Norderney